Koch Industries Inc. raised its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 14,908.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 413,028 shares of the medical instruments supplier’s stock after purchasing an additional 410,276 shares during the quarter. Koch Industries Inc. owned approximately 0.56% of West Pharmaceutical Services worth $409,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of WST. BlackRock Inc. increased its position in West Pharmaceutical Services by 8,884.7% during the 1st quarter. BlackRock Inc. now owns 5,805,036 shares of the medical instruments supplier’s stock valued at $473,749,000 after purchasing an additional 5,740,426 shares during the period. Riverbridge Partners LLC purchased a new position in West Pharmaceutical Services during the 2nd quarter valued at $48,340,000. Vanguard Group Inc. increased its position in West Pharmaceutical Services by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 6,440,844 shares of the medical instruments supplier’s stock valued at $525,637,000 after purchasing an additional 392,516 shares during the period. Renaissance Technologies LLC increased its position in West Pharmaceutical Services by 7,670.7% during the 2nd quarter. Renaissance Technologies LLC now owns 318,600 shares of the medical instruments supplier’s stock valued at $30,114,000 after purchasing an additional 314,500 shares during the period. Finally, FMR LLC increased its position in West Pharmaceutical Services by 198.9% during the 2nd quarter. FMR LLC now owns 388,625 shares of the medical instruments supplier’s stock valued at $36,733,000 after purchasing an additional 258,611 shares during the period. 90.70% of the stock is currently owned by institutional investors and hedge funds.

WST has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. BidaskClub downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Jefferies Group LLC raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their price objective for the company from $96.00 to $115.00 in a research report on Friday, September 15th. Finally, Stephens initiated coverage on shares of West Pharmaceutical Services in a research report on Tuesday, October 3rd. They set an “equal weight” rating and a $99.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $107.00.

TRADEMARK VIOLATION NOTICE: “West Pharmaceutical Services, Inc. (WST) Shares Bought by Koch Industries Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/west-pharmaceutical-services-inc-wst-shares-bought-by-koch-industries-inc/1634681.html.

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) traded up 0.20% on Monday, reaching $95.36. 15,119 shares of the company’s stock were exchanged. The stock has a market cap of $7.06 billion, a price-to-earnings ratio of 40.93 and a beta of 1.11. The company’s 50 day moving average is $92.70 and its 200-day moving average is $91.36. West Pharmaceutical Services, Inc. has a one year low of $70.17 and a one year high of $99.91.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The business had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406.00 million. During the same period last year, the company earned $0.59 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post $2.68 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be given a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 22.22%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.